Nouspikel T, Gjinovci A, Li S, Iynedjian P B
Division of Clinical Biochemistry, University of Geneva School of Medicine, Switzerland.
FEBS Lett. 1992 Apr 13;301(1):115-8. doi: 10.1016/0014-5793(92)80222-3.
Amylin appears to interfere with the action of insulin in muscle and possibly in liver. We have attempted to detect a direct antagonism between amylin and insulin in cultured rat hepatocytes. The stimulation of glucokinase gene expression was used as a marker of insulin action. Amylin proved ineffective in suppressing subsequent accumulation of glucokinase mRNA in response to maximal or submaximal doses of insulin. When applied to cells already induced by prior incubation with insulin alone, amylin failed to reverse induction, in contrast to the effectiveness of glucagon under the same conditions. Thus, amylin is not a physiological antagonist of insulin in the control of hepatic glucokinase gene expression.
胰淀素似乎会干扰胰岛素在肌肉中以及可能在肝脏中的作用。我们试图在培养的大鼠肝细胞中检测胰淀素和胰岛素之间的直接拮抗作用。将葡萄糖激酶基因表达的刺激用作胰岛素作用的标志物。结果表明，在给予最大剂量或亚最大剂量胰岛素后，胰淀素在抑制葡萄糖激酶mRNA的后续积累方面无效。与单独用胰岛素预先孵育已诱导的细胞相比，当将胰淀素应用于这些细胞时，它无法逆转诱导作用，而在相同条件下胰高血糖素却有效。因此，在肝脏葡萄糖激酶基因表达的调控中，胰淀素不是胰岛素的生理性拮抗剂。
